Shun Yamamoto

Years Active: 2020-2023
Publications (10 Years): 6

National Cancer Centre

This page only lists publications with an associated author ORCID identifier.

Affiliation History

National Cancer Centre Apr 01 2016

Japan

Doctor :: Department of gastrointestinal medical oncology

Publications

Go Ikeda, Jun Miyakoshi, Shun Yamamoto, Ken Kato
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Future oncology (London, England) 20 (11) (2023)
Go Ikeda, Jun Miyakoshi, Shun Yamamoto, Ken Kato
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Future oncology (London, England) (2023)
Go Ikeda, Jun Miyakoshi, Shun Yamamoto, Ken Kato
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. Future oncology (London, England) 20 (11) (2023)
Kentaro Harada, Shun Yamamoto, Ken Kato
Pembrolizumab for the treatment of advanced esophageal cancer. Future oncology (London, England) 18 (18) (2022)
Shun Yamamoto, Ken Kato
Immuno-oncology for esophageal cancer. Future oncology (London, England) 16 (32) (2020)
Shun Yamamoto, Ken Kato, Hiroyuki Daiko, Takashi Kojima, Hiroki Hara, Tetsuya Abe, Yasuhiro Tsubosa, Kengo Nagashima, Kazunori Aoki, Yukihiro Mizoguchi, Shigehisa Kitano, Shinichi Yachida, Satoshi Shiba, Yuko Kitagawa
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future oncology (London, England) 16 (19) (2020)

Shun Yamamoto.css-eqlu8i{font-size:small;padding-left:4px;}